the iBerry Study 2.0 - Research in social, psychological and physical development in youth

Published: 29-11-2018 Last updated: 12-04-2024

The iBerry Study has two main study objectives:1. Describing long-term prognosis of subthreshold symptoms in terms of course (transition to several psychiatric disorders, chronicity, recurrence, co-morbidity) and public health consequences (...

Ethical review Approved WMO **Status** Recruiting

Health condition type Psychiatric disorders NEC **Study type** Observational invasive

Summary

ID

NL-OMON55362

Source

ToetsingOnline

Brief title

the iBerry Study 2.0

Condition

Psychiatric disorders NEC

Synonym

(Child) psychiatric disorders

Research involving

Human

Sponsors and support

Primary sponsor: Psychiatrie

Source(s) of monetary or material Support: Ministerie van OC&W,ESPRi-instellingen:

Yulius; BAVO Europoort; Antes; GGZ Breburg; GGZ WNB; GGZ Delfland

1 - the iBerry Study 2.0 - Research in social, psychological and physical developmen ... 7-05-2025

Intervention

Keyword: Adolescents, Epidemiology, Psychiatry

Outcome measures

Primary outcome

- Behavioral and emotional problems in adolescents
- Psychiatric disorders
- Lifestyle and substance use
- Family characteristics (family coherence, parent-child interaction, conflict

tactics, communication style)

- Social support and disclosure / bullying
- Genetics
- Epigenetics
- Haircortisol
- Life events
- Personality
- Sexuality
- Fysical characteristics (sleep and movement, quantitative sensory testing,

advanced glycation end products)

Secondary outcome

N.A.

Study description

Background summary

2 - the iBerry Study 2.0 - Research in social, psychological and physical developmen ... 7-05-2025

In August 2014 the iBerry Study started the first phase of a longitudinal study in the development of psychiatric disorders, in cooperation with the Dutch Centre for Youth and Family in the Rijnmond region (MEC-2014-416). In high school, adolescents aged 12 to 14 years were screened on emotional and behavioral problems as part of standard preventive youth healthcare. In the second phase of the iBerry Study selected participants were invited for their first visit at the research center as part of the iBerry Study baseline measurement (MEC-2015-007). The current study is the first follow-up and takes place two to three years after baseline. The objective of the first follow-up is to further identify key factors in transition of sub-threshold symptoms to psychiatric disorders.

Study objective

The iBerry Study has two main study objectives:

- 1. Describing long-term prognosis of sub-threshold symptoms in terms of course (transition to several psychiatric disorders, chronicity, recurrence, co-morbidity) and public health consequences (disability, costst)
- 2. Examining genetic, biological and psychosocial determinants of the transition from sub-threshold symptoms to psychiatric disorders

Study design

The iBerry Study is designed as a prospective observational study.

Study burden and risks

Assessments of participating adolescents consists of questionnaires, interviews, physical examination, respectively measurement of length, weight, skin fold, actigraphy, AGE-reader (advanced glycation end products), QST-measurement (quantitative sensory testing), venapuncture and collection of hair. All measurements are done child friendly under supervision of professionals. The total time load of the visit is no more than three hours. The actigraphy has an additional time load of 1,5 hour divided over 9 days (10 minutes per day)

Assessment in participating parents consists of questionnaires, interviews, physical examination, respectively measurement of length, weight, skin fold, AGE-reader (advanced glycation end products), QST-measurement (quantitative sensory testing), venapuncture and collection of hair. The total time load of the visit will take no more than three hours.

Participants in the iBerry Study 2.0 do not directly benefit from participation, apart from a small gratification (giftcard t.t.v.o. 35 euros in participation of all assessments). Participation may lead to early detection of serious psychiatric conditions, for which effective treatment is available. If a participant is diagnosed with a serious psychiatric condition with possible dangers for themselves or others, they will be informed and advised to see

their general practitioner and request referral for mental health care specialists.

Contacts

Public

Selecteer

Dr. Molewaterplein 40 Rotterdam 3015 GD NL

Scientific

Selecteer

Dr. Molewaterplein 40 Rotterdam 3015 GD NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age

Adolescents (12-15 years) Adolescents (16-17 years) Adults (18-64 years) Elderly (65 years and older)

Inclusion criteria

Participation in the iBerry Study, phase 2, baseline. Written informed consent for approach follow-up research. Written informed consent for participation in the iBerry Study 2.0.

Exclusion criteria

Temporarily or full withdrawal of participation in the iBerry Study Decease of the adolescent

Study design

Design

Study type: Observational invasive

Intervention model: Other

Allocation: Non-randomized controlled trial

Masking: Open (masking not used)

Control: Active

Primary purpose: Basic science

Recruitment

NL

Recruitment status: Recruiting
Start date (anticipated): 20-03-2019

Enrollment: 1120
Type: Actual

Ethics review

Approved WMO

Date: 29-11-2018

Application type: First submission

Review commission: METC Erasmus MC, Universitair Medisch Centrum Rotterdam

(Rotterdam)

Approved WMO

Date: 23-04-2020

Application type: Amendment

Review commission: METC Erasmus MC, Universitair Medisch Centrum Rotterdam

(Rotterdam)

Approved WMO

Date: 25-02-2021
Application type: Amendment

Review commission: METC Erasmus MC, Universitair Medisch Centrum Rotterdam

(Rotterdam)

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register ID

CCMO NL67275.078.18